CUMC Research Pharmacy

New York, New York 10032

0 studies enrolling now · 9 studies all time

What they study most

Alzheimer Disease, Astrocytoma, Bladder Cancer, Colorectal Cancer, Head and Neck Cancer, Healthy, Hepatocellular Cancer, Human Immunodeficiency Virus, Malignant Glioma, Melanoma, Non-Small-Cell Lung Cancer, Oligodendroglioma

Studies at this site

• Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease — Completed
• Study of PF-07263689 in Participants With Selected Advanced Solid Tumors — Stopped early
• PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) — Withdrawn before enrolling
• Prospective Observational Epidemiologic Study of Maraviroc's Safety — Completed
• First in Patient Study for PF-06840003 in Malignant Gliomas — Stopped early
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis — Completed
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis — Completed
• A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease — Completed